Loss of heterozygosity at 6p21 underling HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas

Tissue Antigens

Volumn 72, Issue 2, 2008, Pages 105-114

  Yang, Y ^a   Zhang, J ^a   Miao, F ^a   Wei, J ^b   Shen, C ^a   Shen, Y ^a   Xie, W ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Human leukocyte antigen class I molecule; Immunohistochemistry; Loss of heterozygosity; Primary esophageal squamous cell carcinoma

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1 HEAVY CHAIN; HLA B ANTIGEN; HLA C ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CHROMOSOME 15Q; CHROMOSOME 6P; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HETEROZYGOSITY LOSS; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 6; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; GENES, MHC CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; PARAFFIN EMBEDDING;

EID: 47549117177     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2008.01078.x     Document Type: Article

References (31)

1. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered class I phenotypes in humans tumors. Immunol Today 1997 : 18 : 89 95.
2. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today 1993 : 14 : 491 3.
3. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003 : 195 : 346 553.
4. Brady CS, Bartholomew JS, Burt DJ et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000 : 55 : 401 11.
5. Tamiya G, Ota M, Katsuyama Y et al. Twenty-six new polymorphic microsatellite markers around the HLA-B, -C and -E loci in the human MHC class I region. Tissue Antigens 1998 : 51 : 337 46.
6. Koopman LA, Mulder A, Corver WE et al. HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens 1998 : 51 : 623 36.
7. Feenstra M, Veltkamp M, van Kuik J et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999 : 54 : 235 45.
8. Nie Y, Yang GY, Song YL et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001 : 22 : 1615 23.
9. Feenstra M, Verdaasdonk M, Van der Zwan AW, de Weger R, Slootweg P, Tilanus M. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell arcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 2000 : 80 : 405 14.
10. Wang X, Liang B, Rebmann V et al. Specificity and functional characteristics of anti-HLA A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens 2003 : 62 : 139 48.
11. Owonikoko T, Loberg C, Gabbert HE, Sarbia M. Comparative analysis of basal and typical squamous cell carcinoma of the esophagus: a molecular biological and immunohistochemical study. J Pathol 2001 : 193 : 155 61.
12. Desai SA, Wang X, Noronha EJ et al. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol 2000 : 165 : 3275 83.
13. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983 : 30 : 2471 8.
14. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA B locus heavy chains permit biochemical characterization of certain HLA C locus products. J Immunol 1986 : 137 : 2299 306.
15. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA A and HLA G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998 : 35 : 177 88.
16. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 1992 : 89 : 466 70.
17. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens- new tools for genetic analysis. Cell 1978 : 14 : 9 20.
18. Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard P, Paul P. Altered pattern of major histocompatibility complex expression in renal carcinoma. American Journal of Pathology 2003 : 162 : 501 8.
19. Cabrera T, Lopez-Nevot MA, Gaforia JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003 : 52 : 1 9.
20. Katzwinkel-Wladarsch S, Lieb M, Helse W, Loscher T, Rinder H. Direct amplification and species determination of microsporidian DNA from stool specimen. Trop Med Int Health 1996 : 1 : 373 8.
21. Ramal LM, Feenstra M, Van der Zwan AW et al. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000 : 55 : 443 8.
22. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK. A technique for retrieving antigens in formalin-fixed, routinely acid decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 1992 : 40 : 787 92.
23. Koene GJ, Arts-Hilkes YH, van der Ven KJ et al. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis. Tissue Antigens 2004 : 64 : 452 61.
24. Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 2003 : 97 : 2203 11.
25. Huang Q, Yu GP, McCormick SA et al. Genetic differences detected by comparative genomic hybridizations in head and neck squamous cell carcinomas from different tumor sites: constructions of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 2002 : 34 : 224 33.
26. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, Van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998 : 18 : 4793 800.
27. Mattijssen V, de Mulder PH, Schalkwijk L, Manni JJ, Van't Hof-Grootenboer B, Ruiter DJ. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991 : 6 : 95 100.
28. Andratschke M, Pauli C, Stein M, Chaubal S, Wollenberg B. MHC Class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer. Anticancer Res 2003 : 23 : 1467 71.
29. Chatterjee A, Pulido HA, Koul S et al. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res 2001 : 61 : 2119 23.
30. Mazurenko N, Attaleb M, Gritsko T et al. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep 1999 : 6 : 859 63.
31. Koopman LA, Correr WE, Van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. Exp Med 2000 : 6 : 961 75.